Objective

Small molecule inhibitors of BET Bromodomain proteins have emerged as an exciting new class of compounds for the potential treatment of a range of cancers and immune-mediated diseases. I’ll describe the discovery and characterisation of these inhibitors and share how we generated and tested hypotheses for potential therapeutic applications in multiple therapeutic areas. I’ll illustrate how and why we chose specific tumour types for the ongoing clinical studies with I-BET, and share the emerging clinical data. I’ll also describe the impact of BET inhibition in immune mediated disease models and show how we’ve used our BET discovery knowledge to target the broader Bromodomain target class.